MELANOMA RECURRENT
Clinical trials for MELANOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new MELANOMA RECURRENT trials appear
Sign up with your email to follow new studies for MELANOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could one year of immunotherapy be enough for advanced melanoma?
Disease control OngoingThis phase 2 trial is testing whether one year of pembrolizumab (an immunotherapy drug) works as well as the standard two-year course for people with advanced melanoma that cannot be surgically removed. The study involves 29 participants in Brazil's public health system and measu…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental antibody trio takes on Hard-to-Treat melanoma
Disease control OngoingThis early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tum…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC